Curasight

The Board of Directors has proposed several agenda items for an upcoming Extraordinary General Meeting. These include extending and increasing authorizations for the Board to raise the company's share capital, both with and without pre-emption rights, by a total nominal amount of DKK 100,000,000. Additionally, they propose authorizing the issuance of up to 106,376,256 warrants to obtain financing, valid until April 16, 2030. The Board also seeks authorization for the meeting chairman to register resolutions and make necessary adjustments as required by authorities. Voting on these proposals requires varying majorities, with specific requirements outlined in the Danish Companies Act. Shareholders are invited to participate, vote, and ask questions, with various options for proxy and postal voting provided. The meeting will be conducted in Danish, and further information is available on the company's website.

Curasight plans to raise approximately DKK 100 million through a Rights Issue, with final terms expected to be announced on April 24, 2025. The subscription price will be set at 65% of the theoretical ex-rights price, but not lower than the nominal share value, capped at DKK 10.24. The Rights Issue is partially covered by subscription and guarantee commitments totaling about 47% of the issue. The record date is tentatively set for May 1, 2025, with a subscription period from May 2 to May 16, 2025. Curasight has renegotiated an outstanding loan with Fenja Capital and secured a bridge loan of DKK 8 million, with warrants issued to Fenja Capital. The funds raised will support ongoing clinical trials and operational costs until mid-2026. The Rights Issue is subject to approval at an Extraordinary General Meeting on April 23, 2025. Sedermera Corporate Finance AB is coordinating the issue, and further details will be published in an information document on April 29, 2025.

Curasight har planerat sin årsstämma till den 28 maj 2025, vilket har uppdaterat den finansiella kalendern och informationen i årsrapporten för 2024. Följande datum är schemalagda för 2025: sista dag för inlämning av aktieägarförslag till årsstämman är den 5 maj, årsrapporten för 2024 publiceras den 13 maj, årsstämman hålls den 28 maj, delårsrapport för Q1 2025 presenteras den 28 maj, delårsrapport för första halvåret 2025 den 28 augusti, och delårsrapport för Q3 2025 den 27 november. För ytterligare information kan Ulrich Krasilnikoff, VD, kontaktas via telefon eller e-post.

Curasight's CEO, Ulrich Krasilnikoff, reported on the company's progress in the fourth quarter, highlighting advancements in their therapeutic and diagnostic platforms, uTREAT® and uTRACE®. They chose brain cancer as the initial clinical focus for uTREAT, aiming for a quicker proof of concept. The company also pursued business development and potential industry collaborations while exploring strategic fundraising despite macroeconomic challenges. Financially, the fourth quarter showed increased losses compared to the same period in 2023, with a gross loss of kDKK -10,210, operating loss of kDKK -11,721, and a loss before tax of kDKK -12,334. Total assets decreased to kDKK 22,314, and the equity ratio dropped to 28.4%. For the full year, the gross loss was kDKK -32,731, operating loss kDKK -40,367, and loss before tax kDKK -42,336. Curasight plans to release its 2024 Annual Report on March 26, 2025.

Curasight har planerat att hålla sin årsstämma den 10 april 2025. Därmed har de uppdaterat sin finansiella kalender för 2025 enligt följande: sista dag för inlämning av aktieägarförslag till årsstämman är den 10 mars 2025; årsstämman hålls den 10 april 2025; årsrapporten för 2024 publiceras den 27 februari 2025, vilket även gäller för delårsrapporten för fjärde kvartalet 2024. Delårsrapporten för första kvartalet 2025 presenteras den 29 maj 2025, för första halvåret 2025 den 28 augusti 2025, och för tredje kvartalet 2025 den 27 november 2025. För mer information kan Ulrich Krasilnikoff, VD, kontaktas via telefon eller e-post.